Opus Genetics completes enrolment in phase 3 trial of OPGx-LCA5
Opus Genetics has completed enrolment in its registrational phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for LCA5-related Leber Congenital Amaurosis (LCA).
Search
Search results
Look Forward – Autumn 2025 – Issue 187
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
Look Forward – Spring 2023 – Issue 179
The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Sirius clinical trial – Exon 13 mutation of USH2A
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Financial support for young people attending conference
Financial support for young people attending conference
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
How we can work together
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
National Peer Support Group
Thursday 8 October 2026, 7.00pm - 8.00pm - via Zoom - Please come and join us for our Autumn meeting where 'This is Your Day to Have Your Say', celebrating both World Sight Day and Retina UK Day.
RECORDING: Annual Conference – 28 September 2024
A recording of the Retina UK Annual Conference on 28 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.